{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Linuron : Questions médicales les plus fréquentes",
"headline": "Linuron : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Linuron : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-10",
"dateModified": "2025-03-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Linuron"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Phénylurées",
"url": "https://questionsmedicales.fr/mesh/D010671",
"about": {
"@type": "MedicalCondition",
"name": "Phénylurées",
"code": {
"@type": "MedicalCode",
"code": "D010671",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.455.426.559.389.703"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Linuron",
"alternateName": "Linuron",
"code": {
"@type": "MedicalCode",
"code": "D008044",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Dirk Springael",
"url": "https://questionsmedicales.fr/author/Dirk%20Springael",
"affiliation": {
"@type": "Organization",
"name": "Division of Soil and Water Management, KU Leuven, Leuven, Belgium."
}
},
{
"@type": "Person",
"name": "Başak Öztürk",
"url": "https://questionsmedicales.fr/author/Ba%C5%9Fak%20%C3%96zt%C3%BCrk",
"affiliation": {
"@type": "Organization",
"name": "Division of Soil and Water Management, KU Leuven, Leuven, Belgium."
}
},
{
"@type": "Person",
"name": "Mikael Pedersen",
"url": "https://questionsmedicales.fr/author/Mikael%20Pedersen",
"affiliation": {
"@type": "Organization",
"name": "Research group for Analytical Food Chemistry, National Food Institute, Technical University of Denmark, 2800 Kgs, Lyngby, Denmark."
}
},
{
"@type": "Person",
"name": "Johannes Werner",
"url": "https://questionsmedicales.fr/author/Johannes%20Werner",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Oceanography, Leibniz Institute for Baltic Sea Research, Rostock, Germany."
}
},
{
"@type": "Person",
"name": "Boyke Bunk",
"url": "https://questionsmedicales.fr/author/Boyke%20Bunk",
"affiliation": {
"@type": "Organization",
"name": "Bioinformatics Department, Leibniz Institute DSMZ, German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The Incidence and Costs of Adverse Events Associated with Antidepressants: Results from a Systematic Review, Network Meta-Analysis and Multi-Country Economic Model.",
"datePublished": "2022-06-07",
"url": "https://questionsmedicales.fr/article/35698594",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2147/NDT.S356414"
}
},
{
"@type": "ScholarlyArticle",
"name": "Is grip strength linked to body composition and cardiovascular risk markers in primary schoolchildren? Cross-sectional data from three African countries.",
"datePublished": "2022-06-06",
"url": "https://questionsmedicales.fr/article/35667732",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bmjopen-2021-052326"
}
},
{
"@type": "ScholarlyArticle",
"name": "Analysis of early neonatal case fatality rate among newborns with congenital hydrocephalus, a 2000-2014 multi-country registry-based study.",
"datePublished": "2022-05-28",
"url": "https://questionsmedicales.fr/article/35633200",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/bdr2.2045"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Causes of Death and Their Influence in Life Expectancy of Children Aged 5-14 Years in Low- and Middle-Income Countries From 1990 to 2019.",
"datePublished": "2022-05-20",
"url": "https://questionsmedicales.fr/article/35669401",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fped.2022.829201"
}
},
{
"@type": "ScholarlyArticle",
"name": "You can't do anything about it, but you can make the best of it: a qualitative analysis of pandemic-related experiences in six European countries.",
"datePublished": "2022-05-20",
"url": "https://questionsmedicales.fr/article/35646295",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/20008198.2022.2065431"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés chimiques organiques",
"item": "https://questionsmedicales.fr/mesh/D009930"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hydrocarbures",
"item": "https://questionsmedicales.fr/mesh/D006838"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hydrocarbures cycliques",
"item": "https://questionsmedicales.fr/mesh/D006844"
},
{
"@type": "ListItem",
"position": 5,
"name": "Hydrocarbures aromatiques",
"item": "https://questionsmedicales.fr/mesh/D006841"
},
{
"@type": "ListItem",
"position": 6,
"name": "Dérivés du benzène",
"item": "https://questionsmedicales.fr/mesh/D001555"
},
{
"@type": "ListItem",
"position": 7,
"name": "Phénylurées",
"item": "https://questionsmedicales.fr/mesh/D010671"
},
{
"@type": "ListItem",
"position": 8,
"name": "Linuron",
"item": "https://questionsmedicales.fr/mesh/D008044"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Linuron - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Linuron",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Linuron",
"description": "Comment diagnostiquer une exposition au linuron ?\nQuels tests peuvent détecter le linuron dans le corps ?\nQuels symptômes indiquent une intoxication au linuron ?\nY a-t-il des tests spécifiques pour les effets du linuron ?\nComment évaluer le risque d'exposition au linuron ?",
"url": "https://questionsmedicales.fr/mesh/D008044?mesh_terms=Developing+Countries&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Linuron",
"description": "Quels sont les symptômes d'une exposition aiguë au linuron ?\nPeut-on avoir des effets chroniques après exposition au linuron ?\nQuels signes cliniques sont associés à une intoxication au linuron ?\nComment différencier les symptômes du linuron d'autres toxines ?\nLes symptômes du linuron peuvent-ils varier selon l'âge ?",
"url": "https://questionsmedicales.fr/mesh/D008044?mesh_terms=Developing+Countries&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Linuron",
"description": "Comment prévenir l'exposition au linuron ?\nQuelles sont les recommandations pour les travailleurs exposés au linuron ?\nLes femmes enceintes doivent-elles éviter le linuron ?\nQuelles mesures de sécurité doivent être prises lors de l'utilisation du linuron ?\nComment informer le public sur les dangers du linuron ?",
"url": "https://questionsmedicales.fr/mesh/D008044?mesh_terms=Developing+Countries&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Linuron",
"description": "Quel traitement est recommandé en cas d'intoxication au linuron ?\nY a-t-il un antidote spécifique pour le linuron ?\nComment traiter les irritations cutanées causées par le linuron ?\nQuels soins d'urgence sont nécessaires en cas d'exposition au linuron ?\nLes traitements varient-ils selon la voie d'exposition au linuron ?",
"url": "https://questionsmedicales.fr/mesh/D008044?mesh_terms=Developing+Countries&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Linuron",
"description": "Quelles complications peuvent survenir après une exposition au linuron ?\nLe linuron peut-il affecter la reproduction ?\nY a-t-il des risques de cancer associés au linuron ?\nComment le linuron affecte-t-il le système nerveux ?\nLes enfants sont-ils plus vulnérables aux effets du linuron ?",
"url": "https://questionsmedicales.fr/mesh/D008044?mesh_terms=Developing+Countries&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Linuron",
"description": "Quels sont les principaux facteurs de risque d'exposition au linuron ?\nL'environnement peut-il influencer l'exposition au linuron ?\nLes personnes ayant des antécédents médicaux sont-elles à risque ?\nLes conditions de travail affectent-elles le risque d'exposition au linuron ?\nLes habitudes de vie influencent-elles l'exposition au linuron ?",
"url": "https://questionsmedicales.fr/mesh/D008044?mesh_terms=Developing+Countries&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une exposition au linuron ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique d'exposition et des tests biologiques spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests peuvent détecter le linuron dans le corps ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des analyses d'urine et de sang peuvent révéler la présence de linuron."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une intoxication au linuron ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des nausées, des vertiges et des irritations cutanées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests spécifiques pour les effets du linuron ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de fonction hépatique et rénale peuvent être effectués pour évaluer les effets."
}
},
{
"@type": "Question",
"name": "Comment évaluer le risque d'exposition au linuron ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation du risque se fait par l'analyse des conditions de travail et des habitudes."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une exposition aiguë au linuron ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes aigus incluent des maux de tête, des nausées et des troubles respiratoires."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des effets chroniques après exposition au linuron ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une exposition prolongée peut entraîner des problèmes respiratoires et dermatologiques."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés à une intoxication au linuron ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes cliniques incluent des éruptions cutanées, des troubles gastro-intestinaux et des vertiges."
}
},
{
"@type": "Question",
"name": "Comment différencier les symptômes du linuron d'autres toxines ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un historique d'exposition et des tests spécifiques aident à différencier les symptômes."
}
},
{
"@type": "Question",
"name": "Les symptômes du linuron peuvent-ils varier selon l'âge ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les enfants et les personnes âgées peuvent présenter des symptômes plus graves."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'exposition au linuron ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des équipements de protection individuelle et suivre les protocoles de sécurité."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations pour les travailleurs exposés au linuron ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs doivent suivre des formations sur la manipulation sécurisée des produits chimiques."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes doivent-elles éviter le linuron ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est conseillé aux femmes enceintes d'éviter l'exposition au linuron en raison des risques."
}
},
{
"@type": "Question",
"name": "Quelles mesures de sécurité doivent être prises lors de l'utilisation du linuron ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Porter des gants, des masques et travailler dans des zones bien ventilées."
}
},
{
"@type": "Question",
"name": "Comment informer le public sur les dangers du linuron ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des campagnes de sensibilisation et des brochures d'information peuvent être mises en place."
}
},
{
"@type": "Question",
"name": "Quel traitement est recommandé en cas d'intoxication au linuron ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut l'élimination de l'exposition et des soins symptomatiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il un antidote spécifique pour le linuron ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas d'antidote spécifique pour le linuron, le traitement est symptomatique."
}
},
{
"@type": "Question",
"name": "Comment traiter les irritations cutanées causées par le linuron ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les irritations cutanées peuvent être traitées avec des crèmes apaisantes et des antihistaminiques."
}
},
{
"@type": "Question",
"name": "Quels soins d'urgence sont nécessaires en cas d'exposition au linuron ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les soins d'urgence incluent le lavage de la peau et l'administration d'oxygène si nécessaire."
}
},
{
"@type": "Question",
"name": "Les traitements varient-ils selon la voie d'exposition au linuron ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements diffèrent selon qu'il s'agit d'une exposition cutanée, orale ou respiratoire."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après une exposition au linuron ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles respiratoires chroniques et des problèmes dermatologiques."
}
},
{
"@type": "Question",
"name": "Le linuron peut-il affecter la reproduction ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent que le linuron peut avoir des effets néfastes sur la reproduction."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de cancer associés au linuron ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours pour évaluer le potentiel cancérigène du linuron."
}
},
{
"@type": "Question",
"name": "Comment le linuron affecte-t-il le système nerveux ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition prolongée peut entraîner des troubles neurologiques et des effets cognitifs."
}
},
{
"@type": "Question",
"name": "Les enfants sont-ils plus vulnérables aux effets du linuron ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les enfants peuvent être plus sensibles aux effets toxiques du linuron en raison de leur développement."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque d'exposition au linuron ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs agricoles et ceux manipulant des pesticides sont les plus exposés."
}
},
{
"@type": "Question",
"name": "L'environnement peut-il influencer l'exposition au linuron ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la proximité des zones agricoles et l'utilisation de pesticides augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les personnes ayant des antécédents médicaux sont-elles à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes avec des problèmes respiratoires préexistants peuvent être plus à risque."
}
},
{
"@type": "Question",
"name": "Les conditions de travail affectent-elles le risque d'exposition au linuron ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des conditions de travail non sécurisées augmentent le risque d'exposition au linuron."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles l'exposition au linuron ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme le jardinage sans protection peuvent augmenter l'exposition."
}
}
]
}
]
}
There is variation in the safety profile of antidepressants. Rates of adverse events along with the costs of treating them can be an important factor influencing the choice of depression treatment. Th...
A systematic literature review was conducted (in Medline, Embase, PsycINFO and CENTRAL) to identify placebo-controlled trials reporting rates of at least one type of sexual dysfunction, weight change,...
Trazodone had the lowest rates of both insomnia (odds ratio 0.66, 95% credible interval 0.31 to 1.38) and anxiety (0.13, <0.01 to 1.80). All antidepressants were associated with increased rates of sex...
Trazodone generally had the best safety profile of the antidepressants evaluated. This led to healthcare costs being lowest for trazodone in all nine European countries, emphasising the importance of ...
Muscular strength represents a specific component of health-related fitness. Hand grip strength (HGS) is used as an indicator for musculoskeletal fitness in children. HGS can also be used as a marker ...
Cross-sectional study....
Public primary schools (grade 1-4) in Taabo (Côte d'Ivoire), Gqeberha (South Africa) and Ifakara (Tanzania)....
Data from 467 children from Côte d'Ivoire (210 boys, 257 girls), 864 children from South Africa (429 boys, 435 girls) and 695 children from Tanzania (334 boys, 361 girls) were analysed....
Body composition (assessed via bioelectrical impedance analysis) was the primary outcome. Cardiovascular risk markers were considered as secondary outcome. Blood pressure was measured with an oscillom...
Across all study sites, higher HGS was associated with lower body fat, higher muscle mass and higher fat-free mass (...
HGS assessment is popular due to its simplicity, feasibility, practical utility and high reliability of measurements. This is one of the first HGS studies with children from sub-Saharan Africa. There ...
ISRCTN29534081....
Congenital hydrocephalus (CH) comprises a heterogeneous group of birth anomalies with a wide-ranging prevalence across geographic regions and registry type. The aim of the present study was to analyze...
Data were provided by 25 registries from four continents participating in the International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR) on births ascertained between 2000 and 20...
A total of 13,112 CH cases among 19,293,280 total births were analyzed. The early neonatal CFR was 5.9 per 100 liveborn cases, 95% confidence interval (CI): 5.4-6.8. The CFR among syndromic cases was ...
Findings of early neonatal CFR and total BPR were highly heterogeneous among registries participating in ICBDSR. Most registries with higher CFR also had higher BPR. Differences were attributable to t...
Although child and adolescent health is the core of the global health agenda, the cause of death and its expected contribution to life expectancy (LE) among those aged 5-14 are under-researched across...
Death rates per 10 years age group including a 5-14-year-old group were calculated by the formula, which used the population and the number of deaths segmented by the cause of death and gender from th...
In 2019, the global mortality rate for children and adolescents aged 5-14 years was 0.522 (0.476-0.575) per 1,000, and its LF was 71.377 years. In different-income regions, considerable heterogeneity ...
The mortality rate for children and adolescents aged 5-14 years among LMICs remains high. Considerable heterogeneity was observed in the main causes of death among regions. According to the main cause...
The complex system of stressors related to the coronavirus disease 2019 (COVID-19) pandemic has affected the global population, provoking a broad range of psychological reactions. Although numerous st...
This qualitative study aimed to explore self-perceived challenges and opportunities related to COVID-19 across six European countries. The overall objective was to provide a differentiated picture of ...
The present study included 7309 participants from Austria, Croatia, Georgia, Greece, Poland, and Portugal. We performed qualitative content analysis according to Mayring analyse open-ended questions r...
Participants' accounts were moderately consistent across the countries. The most prominent themes regarding stressful and negative pandemic aspects included:...
Participants experienced various challenges, but also shared several positive pandemic consequences and recommendations to cope with the pandemic. These first-hand data could inform mental health prac...
We examined COVID-19-related experiences in 7309 adults from six European countries.Besides challenges, participants identified many positive pandemic consequences.Participants' recommendations to cop...
The effects of recently implemented colorectal cancer screening programmes in Europe on colorectal cancer mortality will take several years to be fully known. We aimed to analyse the characteristics a...
We conducted this population-based study in nine European countries for which data on mode of detection were available (Belgium, Denmark, England, France, Italy, Ireland, the Netherlands, Slovenia, an...
228 667 colorectal cancer cases were included in the analyses. Proportions of screen-detected cancers varied widely across countries and regions. The highest proportions (40-60%) were found in Sloveni...
The proportion of colorectal cancer cases detected by screening varied widely between countries. However, in all countries, screen-detected cancers had a more favourable stage distribution than cancer...
Deutsche Krebshilfe....
To estimate the global burden of myocarditis in the general population from 1990 to 2021....
Data on myocarditis were retrieved from the Global Burden of Disease Study 2021. Incidence, deaths, and disability-adjusted life years (DALYs), along with their age-standardized rates (ASRs) per 100 0...
Although the ASRs of incidence, deaths, and DALYs significantly decreased from 1990 to 2021, the global number of incidences, deaths, and DALYs increased substantially. Certain populations, including ...
The European Academy of Neurology (EAN) has adhered to the global plan for reducing the burden of neurological disorders and promoting brain health launched by the World Health Organisation (WHO), the...
The EAN survey on the current state of national brain health policies was conducted among the 47 presidents of the NNSs affiliated with the EAN, with the aim of developing the best strategy for close ...
From June 2023 to February 2024, 36/47 responses (77%) were collected. Among respondents, 67% were in contact with their Ministry of Health and 78% were aware of and in contact with one or more nation...
Our findings suggest good awareness of the importance of brain health and of the strategies implemented at the national level among the EAN-affiliated NNSs and representatives. Efforts towards improve...
Caribbean health research has overwhelmingly employed measures developed elsewhere and rarely includes evaluation of psychometric properties. Established measures are important for research and practi...
The nationwide HUN-CANCER EPI study examined cancer incidence and mortality rates in Hungary from 2011 to 2019....
Using data from the National Health Insurance Fund (NHIF) and Hungarian Central Statistical Office (HCSO), our retrospective study analyzed newly diagnosed malignancies between Jan 1, 2011, and Dec 31...
The number of newly diagnosed cancer cases decreased from 60,554 to 56,675 between 2011-2019. Age-standardized incidence rates were much lower in 2018, than previously estimated (475.5 vs. 580.5/100,0...
We found a lower incidence of newly diagnosed cancer cases for Hungary compared to previous estimates, and decreasing trends in cancer incidence and mortality, in line with global findings and the dec...